trending Market Intelligence /marketintelligence/en/news-insights/trending/rIePglceRI_ArJ7pXHwHeg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

ANI Pharmaceuticals buys US rights to 4 AstraZeneca drugs for $46.5M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

ANI Pharmaceuticals buys US rights to 4 AstraZeneca drugs for $46.5M

ANI Pharmaceuticals, Inc. said it purchased U.S. rights to four of AstraZeneca PLC's drugs for $46.5 million.

The drugs include hypertension treatments Atacand and Atacand HCT, breast cancer medicine Arimidex, and Casodex for prostate cancer.

AstraZeneca, the U.K.'s second-biggest drugmaker, will continue to market and supply these four drugs outside the U.S. The British drugmaker has been selling off older assets as it focuses on developing new products.

The payment of $46.5 million would be in cash, royalties and sales-based milestones. ANI funded the acquisitions through a combination of cash and debt.

According to market intelligence firm IMS Health, these products generated about $19 million in U.S. sales during the trailing 12 months through October 2017.

ANI, based in Baudette, Minn., sells both branded and generic prescription drugs.